News | May 27, 2008

Study Shows SEDASYS System Reduces Risk of Over Sedation of Propofol

May 28, 2008 - Ethicon Endo-Surgery recently released the results of its pivotal trial that demonstrated physician/nurse teams using the SEDASYS System reduced the risk of over sedation with propofol in patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy), and disorders of the upper gastrointestinal tract (EGD).

The study included 1,000 subjects who underwent sedation for colonoscopy and EGD at eight sites and compared the SEDASYS System to the current standard of care for sedation (midazolam plus fentanyl or meperidine). Results were included in Ethicon Endo-Surgery’s FDA premarket application for approval of the SEDASYS System, which is currently in review with the FDA. 



“During the trial, the system made it possible for gastroenterologists to maintain minimal to moderate sedation with propofol, and helped prevent patients from entering deep sedation, which is traditionally associated with propofol,” said Daniel Pambianco, M.D., FACG, medical director of Charlottesville Medical Research and trial investigator. “The system offers a way to personalize the level of sedation appropriate for each patient because it combines propofol delivery with sophisticated monitoring to help us better control and predict the patient’s sedation level.”

The trial showed patients who received sedation with the SEDASYS System experienced fewer and less significant oxygen desaturation events, a clinical sign of over sedation, than patients sedated with current standard of care. The trial demonstrated this by achieving its primary endpoint of area under the curve (AUC) of oxygen desaturation (SpO2

“Patients understand that recovery from sedation takes time after a colonoscopy, but with propofol, they recuperate quicker and are functional sooner,” said Dr. Pambianco. “GIs have been performing procedures with current standard of care sedatives for years and maintaining a constant sedation level in patients can be daunting. The novelty of this system is that it has the potential to accurately tune into my patient’s sedation needs by following their vital signs and delivering propofol in a precise manner.”

For more information: www.ddw.org, www.ethiconendo.com

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
Sun Nuclear Surpasses 100 Units Shipped Milestone With SRS MapCheck
News | Quality Assurance (QA) | October 26, 2018
Sun Nuclear Corp. announced the 100th shipment of its new SRS MapCheck for stereotactic radiosurgery (SRS). The...
myQA Daily is optimized for daily QA workflow efficiency.
News | Quality Assurance (QA) | October 18, 2018
myQA Daily from IBA Dosimetry enables fast as well as high-quality daily...
IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring
News | Radiation Therapy | October 17, 2018
IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
IBA Dosimetry Launches SmartScan Automated and Guided Beam Commissioning Solution
Technology | Quality Assurance (QA) | July 27, 2018
IBA (Ion Beam Applications S.A.) announced the market launch of its new SmartScan solution at the 60th annual American...
American Cancer Society Updates Colorectal Cancer Screening Guideline
News | Colonoscopy Systems | May 30, 2018
An updated American Cancer Society guideline says colorectal cancer screening should begin at age 45 for people at...